New Edge Advisors, LLC Crispr Therapeutics Ag Transaction History
New Edge Advisors, LLC
- $16.2 Billion
- Q1 2025
A detailed history of New Edge Advisors, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, New Edge Advisors, LLC holds 3,372 shares of CRSP stock, worth $218,370. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,372
Previous 7,420
54.56%
Holding current value
$218,370
Previous $292,000
60.96%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CRSP
# of Institutions
480Shares Held
63.9MCall Options Held
2.16MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$658 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$393 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$246 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$180 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.54MShares$164 Million1.16% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $5.05B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....